https://www.thebodypro.com/author/david-alain-wohl
David Alain Wohl, M.D. Img

David Alain Wohl, M.D.

David Alain Wohl, M.D., is a professor of medicine in the Division of Infectious Diseases at the University of North Carolina (UNC). He is site leader of the UNC AIDS Clinical Trials Unit at Chapel Hill, director of the North Carolina AIDS Education and Training Center (AETC), and co-director of HIV services for the North Carolina state prison system. In 2014, he became co-director of the UNC-Duke Clinical RM Ebola Response Consortium.

Dr. Wohl's research aims to optimize the treatment of HIV, including identifying the most effective therapeutic approaches and minimizing the adverse effects of therapy. He is also active in investigations focused on populations vulnerable to HIV, such as the incarcerated. He is active within the U.S. AIDS Clinical Trials Group and HIV Prevention Trials Network and served two terms as a member of the U.S. Department of Health and Human Services Antiretroviral Guidelines Panel.

As part of the response to the 2013-2016 Ebola outbreak in West Africa, Dr. Wohl led UNC clinical research efforts to test interventions for Ebola Virus Disease in Liberia and now directs a clinical cohort of Ebola survivors.

In addition to his research and administrative activities, Dr. Wohl maintains a large HIV continuity clinic at UNC.

Disclosures

Dr. Wohl has attended advisory boards for Abbott Laboratories, Tibotec, Janssen Pharmaceuticals, ViiV Healthcare, and Gilead Sciences. In addition, his university has received support for his research from Gilead Sciences and ViiV Healthcare. These disclosures were last updated on November 17, 2017.

Latest by David Alain Wohl, M.D.

strips of paper with headlines over microscope science background
Features

Top 10 HIV Clinical Developments of 2019

Will a given development in HIV make a difference in the clinic? Will it change practice? Is this something I should know if I take care of people living with HIV? The answer to each of these must be yes for the story to make the list.

Weight Gain and HIV Antiretrovirals photo illustration
Features

Weight Gain and HIV Antiretrovirals: Lipodystrophy for the Integrase Era

In a busy year buzzing with the flight of potentially revolutionary new HIV medications, evidence of large weight increases accompanying dolutegravir and bictegravir has been a bombshell.

Two-Drug TANGO photo illo
Features

TANGO, the Most Relevant Two-Drug Antiretroviral Therapy Trial of the Year

Whether lamivudine/dolutegravir is sufficient to achieve and maintain viral suppression was last year's question. As we move to 2020, a new question could be asked: Are three-drug regimens still necessary?

F/TAF for PrEP photo illo
Features

And Then There Were Two: FTC/TAF Is Also PrEP

Given similar efficacy and the renal and bone benefits, TAF/FTC should be favored over TDF/FTC. But as David Wohl, M.D., explains, the reality isn't so simple.

Dolutegravir and Pregnancy photo illo
Features

Tsepamo Study Provides Critical Update on Neural Tube Defects and Dolutegravir

A lot of pregnancies in Botswana were anxiously followed after results from the Tsepamo study were revealed in late 2018. Updated data provide a medium-sized sigh of relief.

Long-Acting Antiretrovirals photo illo
Features

ATLAS, FLAIR, and the Upcoming Arrival of Long-Acting Injectable HIV Treatment

The likely launch of injectable cabotegravir/rilpivirine in early 2020 will be interesting, writes David Wohl, M.D. One big question: How smoothly will the rollout go?

Islatravir photo illo
Features

Islatravir Is Potent and Long-Lasting -- and May Be Having an Identity Crisis

This is clearly an antiretroviral not built for daily administration. But then what is it destined for?

The DAWNING Study photo illo
Features

DAWNING Study Casts New Light on the Details of Resistance

The findings will help providers manage patients who have known or potential resistance to NRTIs, but who we want to place on a simplified antiretroviral regimen.

Doxycycline for STIs photo illo
Features

Doxycycline for Bacterial STI Prevention: A Different Type of PrEP

An international team of experts conducted a thoughtful review of existing research regarding the use of doxycycline for STI prevention. Do the risks of its use outweigh the benefits?

Suicide Rates photo illo
Features

The Tangled Knot of Suicide Rates Among People Living With HIV

Sobering data make clear that in HIV clinics, depression screening is as important as STI screening.